Therapy of Canine Hyperlipidemia with Bezafibrate

• Published in: Journal of veterinary internal medicine 2017-05, Vol.31 (3), p.717-722
• Main Authors: De Marco, V., Noronha, K.S.M., Casado, T.C., Nakandakare, E.R., Florio, J.C., Santos, E.Z., Gilor, C.
• Format: Article
• Language: English
• Subjects: Administration, Oral; Animals; Bezafibrate - administration & dosage; Bezafibrate - therapeutic use; Cholesterol; Dog Diseases - blood; Dog Diseases - drug therapy; Dogs; Female; Hyperadrenocorticism; Hyperlipidemias - drug therapy; Hyperlipidemias - veterinary; Hypolipidemic Agents - administration & dosage; Hypolipidemic Agents - therapeutic use; Male; Peroxisome proliferator‐activated receptor; Prospective Studies; Schnauzer; SMALL ANIMAL; Treatment Outcome; Triglyceride
• ISSN: 0891-6640; 1939-1676
• DOI: 10.1111/jvim.14701

Background Bezafibrate (BZF) is effective in the treatment of hypertriglyceridemia in human patients, but there are no data on its use in dogs. Objective To assess the safety of BZF in hyperlipidemic dogs and its efficacy in decreasing serum triglyceride (TG) and cholesterol (CHO) concentrations. Animals Forty‐six dogs, 26 females and 20 males, mean (±SD) age of 9 (±3) years, with TG ≥150 mg/dL (33 dogs also were hypercholesterolemic [>300 mg/dL]). Methods Prospective, uncontrolled clinical trial. Dogs were treated with bezafibrate once daily, using 200 mg tablets at a dosage of 4–10 mg/kg (depending on body weight). Serum TG and CHO concentrations and alanine aminotransferase (ALT) and creatine kinase (CK) activity before and after 30 days of treatment were compared. Results Sixteen dogs (34.8%) had primary hyperlipidemia, and 30 dogs (65.2%) had secondary hyperlipidemia (including spontaneous hyperadrenocorticism [41.3%, n = 19/46], chronic treatment with glucocorticoids [10.8%, n = 5/46], and hypothyroidism [15.2%, n = 7/46]). After 30 days, serum TG concentration normalized (